South African Core Lab Adopts Affymetrix Technology for Genomic Studies
October 07 2008 - 8:00AM
Business Wire
Affymetrix Inc., (Nasdaq:AFFX) today announced that one of South
Africa�s largest public core labs has begun offering genomic
research on the Affymetrix GeneChip� platform. The Centre for
Proteomic and Genomic Research (CPGR) is using many Affymetrix
GeneChip arrays, such as the exon array and the SNP Array 6.0, to
explore applications with molecular diagnostics potential,
large-scale genotyping and novel ways of advancing drug research
and development across the country. The CPGR supports scientists
particularly in biomedicine and plant biotechnology. It has a
particular interest in translational research, advancing scientific
findings from the bench into the clinic. The Centre was founded in
2006 to provide state-of-the-art analytical services, technical
expertise, project support and collaborative research capabilities
in genomics and proteomics. �At the CPGR, our aim is to facilitate
high-quality research and enable the growth of existing southern
African biotech companies,� said Reinhard Hiller, Ph.D., managing
director of the CPGR. �The range of projects we work on is
particularly diverse, so we appreciate the ability of Affymetrix to
offer products that meet all our customers� needs, from toxicology
to gene expression and genotyping.� �The CPGR has assembled a team
of world-class scientists to nourish the development of new biotech
leaders by translating academic research into novel intellectual
property and commercial ventures,� said Kevin King, president of
Affymetrix. �With its adoption of the entire portfolio of array
products available on our integrated microarray platform, the
Centre is setting new standards for microarray-based research which
we believe will lead to important solutions for some of the
region�s most pressing diseases.� About Affymetrix Affymetrix
GeneChip� microarray technology is the industry-standard tool for
analyzing complex genetic information. After inventing microarray
technology in the late 1980s, Affymetrix scientists have been
dedicated to developing innovative products that provide
researchers with a more complete view of the genome. These products
continue to accelerate genetic research and enable scientists to
develop diagnostics and tailor treatments for individual patients
by identifying and measuring the genetic information associated
with complex diseases. Today, Affymetrix technology is used by the
world�s top pharmaceutical, diagnostic and biotechnology companies,
as well as leading academic, government and not-for-profit research
institutes. More than 1,700 systems have been shipped around the
world and more than 13,000 peer-reviewed papers have been published
using the technology. Affymetrix is headquartered in Santa Clara,
Calif., and has manufacturing facilities in Sacramento, Calif.,
Cleveland, Ohio, and Singapore. The company has about 1,100
employees worldwide and maintains sales and distribution operations
across Europe and Asia. For more information about Affymetrix,
please visit the company�s website at www.affymetrix.com. About
CPGR The Centre for Proteomic & Genomic Research (CPGR) is an
integrated core technology facility, founded in South Africa in
2006 as a not-for-profit organization through a grant provided by
the Department of Science and Technology (DST) by way of its
vehicles the Cape Biotech Trust CBT) and PlantBio (PB). Visit
www.cpgr.org.za for more information or contact info@cpgr.org.za
with specific requests. Forward-looking Statements All statements
in this press release that are not historical are �forward-looking
statements� within the meaning of Section 21E of the Securities
Exchange Act as amended, including statements regarding Affymetrix�
�expectations,� �beliefs,� �hopes,� �intentions,� �strategies� or
the like. Such statements are subject to risks and uncertainties
that could cause actual results to differ materially for Affymetrix
from those projected, including, but not limited to: risks and
uncertainties relating to commercial success of the agreement with
the Centre for Proteomic and Genomic Research discussed in this
press release; risks of the company�s ability to achieve and
sustain higher levels of revenue, higher gross margins and reduced
operating expenses; uncertainties related to technological
approaches, manufacturing and product development; personnel
retention; uncertainties related to cost and pricing of Affymetrix
products; dependence on collaborative partners; uncertainties
related to sole-source suppliers; risks associated with past and
future acquisitions; uncertainties relating to FDA and other
regulatory approvals; competition; risks relating to intellectual
property of others and the uncertainties of patent protection and
litigation. These and other risk factors are discussed in
Affymetrix� Form 10-K for the year ended December 31, 2007, and
other SEC reports, including its Quarterly Reports on Form 10-Q for
subsequent quarterly periods. Affymetrix expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in Affymetrix� expectations with regard thereto
or any change in events, conditions or circumstances on which any
such statements are based. NOTE: Affymetrix, the Affymetrix logo
and GeneChip� are registered trademarks owned or used by Affymetrix
Inc.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024